Testing the drug repotrectinib for ROS1 lung cancer that has spread to the brain
Official title: Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests a drug called repotrectinib in people whose lung cancer has spread to the brain.
Read our full plain-language summary
What the trial team says
REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.
Key facts
- Registry number
- NCT06315010
- Stage of testing
- Phase 2
- Conditions studied
- NSCLC, Brain Metastases, ROS1 Gene Rearrangement
Where it is running
This trial lists 17 sites.
-
Alicante
- Hospital de Vinalopó (Elche)
-
Austria
- Medizinische Universität Graz (Graz)
- Medical University of Vienna (Vienna)
-
Barcelona
- Hospital Universitari Vall d'Hebron (Barcelona)
- UOMI Cancer Center (Barcelona)
-
Germany
- Ludwig-Maximilians-University Munich (München)
-
Girona
- Institut Català d' Oncologia Girona (ICO) (Girona)
-
Madrid
- Hospital Beata María Ana (Madrid)
-
Spain
- Hospital General Universitario Dr. Balmis (Alicante)
- Hospital de Cruces (Barakaldo)
- Hospital Universitario de León (León)
- Hospital Lucus Agusti (Lugo)
- Hospital Universitario Vithas Madrid La Milagrosa (Madrid)
- Hospital Clínico Universitario Virgen de la Arrixaca (Murcia)
- Complejo Hospitalario Universitario de Santiago (CHUS) (Santiago de Compostela)
- Hospital Clínico Universitario de Valencia (Valencia)
-
Tarragona
- Hospital Universitari Sant Joan de Reus (Reus)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.